Biologic approaches to the treatment of gastrointestinal malignancy

Current Opinion in Oncology

Volumn 14, Issue 4, 2002, Pages 431-438

  Rosen, Lee S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ANGIOGENESIS INHIBITOR; ANGIOZYME; BEVACIZUMAB; CEAVAC; CETUXIMAB; CYTOTOXIC AGENT; EDRECOLOMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GASTRIMMUNE; GASTRIN 17; GASTRIN ANTAGONIST; GEFITINIB; GEMCITABINE; ISIS 2503; LONAFARNIB; MONOCLONAL ANTIBODY; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RIBOZYME; SEMAXANIB; SEMAXINIB; TIPIFARNIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB; ENDOTHELIAL CELL GROWTH FACTOR; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; LYMPHOKINE; SIGNAL PEPTIDE; TRANSFERASE; VASCULOTROPIN A;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DRUG MECHANISM; DRUG RESEARCH; GASTROINTESTINAL SYMPTOM; HUMAN; ONCOGENE RAS; PRIORITY JOURNAL; REVIEW; DRUG ANTAGONISM; DRUG EFFECT; GASTROINTESTINAL TUMOR; GENETICS; IMMUNE SYSTEM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALKYL AND ARYL TRANSFERASES; ANGIOGENESIS INHIBITORS; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; GASTROINTESTINAL NEOPLASMS; GENES, RAS; HUMAN; IMMUNE SYSTEM; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SUPPORT, NON-U.S. GOV'T; FARNESYLTRANSTRANSFERASE; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035988136     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200207000-00011     Document Type: Review

References (62)

1. Special report: Drugs in the pipeline
2. A cautious awe greets drugs that eradicate tumors in mice: Cancer research by Dr, Judah Folkman on angiostatin and endostatin: Hope in the lab
3. Vascular endothelial growth-factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
4. Isolation of putative progenitor endothelial cells for angiogenesis
5. Different signal-transduction properties of KDR and FLT1, 2 receptors for vascular endothelial growth-factor I
6. Vascular-permeability factor vascular endothelial growth-factor, microvascular hyperpermeability, and angiogenesis
7. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
8. Vascular endothelial growth factor and its receptors
9. Analysis of biologic effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2): A reassessment using novel receptor-specific vascular endothelial growth factor mutants
10. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
11. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor-growth in vivo
12. Inhibition of tumor-growth and metastasis by an immunoneutralizing monoclonal-antibody to human vascular endothelial growth-factor vascular-permeability factor (121)
13. Glioblastoma growth inhibited in vivo by dominant negative Flk-1 mutant
14. Association of vascular endothelial growth-factor expression with tumor angiogenesis and with early relapse in primary breast-cancer
15. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma
16. Histochemical study of vascular endothelial growth factor in squamous cell carcinoma of the esophagus
17. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer
18. Vascular endothelial growth factor expression in early stage ovarian carcinoma
19. Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma
20. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells
21. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor
22. Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site
23. Molecular and biologic properties of vascular endothelial growth factor
24. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer
25. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
26. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function
27. A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer
28. Angiozyme: A novel angiogenesis inhibitor
29. Phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK222584 on a twice daily schedule in patients with advanced cancer
30. Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging of 2 phase I studies of the BVEGF inhibitor PTK 787/ZK 222584 in patients with liver metastases from colorectal cancer
31. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor
32. The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia
33. Interrelationship between transforming growth factor-alpha and epidermal growth-factor receptor in advanced gastric-cancer
34. Clinical results of transhiatal esophagectomy for carcinoma of the lower thoracic esophagus according to biologic markers
35. The prognostic-significance of proliferating cell nuclear antigen, epidermal growth-factor receptor, and MDR gene-expression in colorectal-cancer
36. Inverse relation between epidermal growth factor receptor expression and radiocurability of murine carcinomas
37. Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells
38. Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas
39. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma
40. Clinicopathologic significance of epidermal growth factor and its receptor in human pancreatic cancer
41. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
42. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
43. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
44. Acne-like rash predicts response in patients treated with Cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
45. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody Cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer
46. Feasibility and pharmacokinetic (PK) trial of ZD 1839 (Iressa™), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced colorectal cancer
47. RAS oncogenes in human cancer: A review
48. Increasing complexity of the ras signaling pathway
49. Harvey murine sarcoma-virus p21 RAS protein-biologic and biochemical significance of the cysteine nearest the carboxy terminus
50. A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biologic and clinical activity
51. Randomized phase II study of SCH66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas
52. A phase I pharmacokinetic (PK) and biologic study of the farnesyl transferase inhibitor (FTI) R115777 and capecitabine in patients (PTS) with advanced solid malignancies
53. A phase I study of the farnesyltransferase (FT) inhibitor BMS-214662 administered as a weekly 1-hour infusion in patients (pts) with advanced solid tumors: Clinical findings
54. Phase II trial of ISIS 2503, an antisense inhibitor of H-ras, in patients (pts) with advanced pancreatic carcinoma (CA)
55. CancerVax, a polyvalent vaccine improves survival in refractory stage IV colon cancer: A phase II trial
56. Theratope® vaccine in metastatic colorectal cancer: Immunogenicity and survival in a dose range study
57. CeaVac anti-idiotype (anti-Id) monoclonal antibody (Mab) treatment for resected colorectal cancer (CRC): Results of a phase II trial
58. G17DT: A new weapon in the therapeutic armoury for gastrointestinal malignancy
59. G17DT therapy may improve the survival of patients with advanced pancreatic carcinoma
60. Phase I/II trial of G17DT in gastric carcinoma
61. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial
62. Edrecolomab (17-1A antibody) alone or in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: Results of a phase III study